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Abstract
Background: This was a prespecified secondary analysis of a randomized trial, which analyzed bone density
following stereotactic body radiotherapy (SBRT) versus conventional three-dimensional conformal radiotherapy
(3DCRT) as part of palliative management of painful spinal metastases.
Methods: Fifty-five patients were enrolled in this single-institutional randomized exploratory trial (NCT02358720).
Participants were randomly assigned to receive SBRT (single-fraction 24 Gy) or 3DCRT (30 Gy/10 fractions).
Quantitative bone density was evaluated at baseline, 3 and 6 months in both irradiated and unirradiated spinal
bodies, along with rates of pathologic fractures and vertebral compression fractures.
Results: As compared to baseline, bone density became significantly higher at 3 and 6 months following SBRT by a
median of 33.8% and 72.1%, respectively (p < 0.01 for both). These figures in the 3DCRT cohort were 32.9% and 41.
2%, respectively (p < 0.01 for both). There were no statistical differences in bone density between SBRT and 3DCRT
at 3 (p = 0.629) or 6 months (p = 0.327). Subgroup analysis of osteolytic metastases showed an increase in bone
density relative to baseline in the SBRT (but not 3DCRT) arm. Bone density in unaffected vertebrae did not show
substantial changes in either group. The 3-month incidence of new pathological fractures was 8.7% in the SBRT
arm vs. 4.3% in the 3DCRT arm.
Conclusions: Despite high ablative doses in the SBRT arm, the significant increase in bone density after 3 and
6 months was similar to that of 3DCRT. Our trial demonstrated a moderate rate of subsequent pathological fracture
after SBRT. Future randomized investigations with larger sample sizes are recommended.
Trial registration: www.clinicaltrials.gov: NCT02358720 on 9nd of February 2015.
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Background
Up to 40% of patients with advanced-stage cancer de-
velop osseous spinal metastases [1]. The associated
pain, immobility, pathological fractures, and neuro-
logical deficits may considerably reduce quality of life.
Conventionally fractionated three-dimensional con-
formal radiotherapy (3DCRT) is the treatment of
choice for painful osseous metastases [2, 3]. However,
spinal stereotactic body radiotherapy (SBRT) is a
promising alternative owing to the ability to deliver
high, ablative doses for durable local control while
protecting adjacent organs-at-risk (OARs) [4–10].
Spinal SBRT has heretofore been primarily utilized
for oligometastatic osseous disease and for re-irradia
tion of osseous metastases [11]. Prospective trials
using SBRT for bone metastases have reported excel-
lent tumor control, appropriate pain response, and
low toxicity rates [12, 13].
However, there are known serious adverse events asso-
ciated with spinal SBRT, such as vertebral compression
fractures (VCFs) [14]. Hence, changes in bone density
following ablative procedures such as SBRT are import-
ant to characterize. No randomized trials comparing
bone density changes with SBRT versus conventional
3DCRT exist to date. This was a prespecified secondary
analysis of a randomized trial, which evaluated bone
density following SBRT versus conventional 3DCRT as
part of palliative management of painful spinal metastases.
Methods
Subjects, recruitment strategy, and eligibility for
enrollment
From November 2014 to March 2017, 60 patients with
histologically confirmed cancer and painful bone metas-
tases of the thoracic or lumbar vertebral column were
randomized in both arms: high-dose single-fraction
SBRT (24 Gy) versus standard fractioned 3DRT (10 ×
3 Gy).
Inclusion criteria were ages 18–80, a Karnofsky per-
formance score [15] ≥ 70, ability to provide written in-
formed consent, a maximum of two irradiated vertebral
bodies per region, a maximum of two different vertebral
regions affected, and tumor distance > 3 mm to the
spinal cord. Exclusion criteria were subjects with signifi-
cant neurological or psychiatric disorders precluding in-
formed consent, previous RT to the given irradiation
site, contraindications for MRI, multiple myeloma or
lymphoma histology, or involvement of the cervical
spine.
In total, five patients were duly excluded. Four patients
in the SBRT arm had an insufficient distance between
tumor and spinal cord. One participant from the control
arm was excluded because of the confirmed diagnosis of
multiple myeloma after randomization. Fifty-five
patients met the inclusion/exclusion criteria and were
enrolled into the trial (Fig. 1).
The randomized trial, registered on clinicaltrials.gov
(NCT02358720), was approved by the Heidelberg Uni-
versity Independent Ethics Committee (Nr. S-431/2013).
Additionally, approval was given from the German Fed-
eral Office of Radiation Protection (BfS).
Design, randomized allocation, and procedures
Details of the study design have been published previ-
ously [16]. The primary endpoint of this randomized,
single-institutional, exploratory trial was pain response
after high-dose single-fraction SBRT versus conventional
3DCRT in patients with painful, previously untreated
spinal metastases. The present study was a prespecified
secondary analysis of bone density, as well as rates of
pathologic fracture and VCF.
A block randomization approach (block size of 6) was
used to ensure that the two groups were balanced. Two
different techniques were evaluated on a 1:1 basis accord-
ing to the randomization list: high-dose, single-fraction
(24 Gy to the 80% isodose line) SBRT versus 30 Gy in 10
fractions of conventional radiotherapy.
The data of the patient records were collected by the
authors. The evaluation included all recorded data up to
the 6-month follow-up interval.
Assessment of the secondary endpoints
Per protocol, bone density in irradiated and unirradiated
vertebral bodies, other pathologic vertebral fractures,
and VCFs were assessed at baseline and at 3 and
6 months after RT. Bone density was assessed with the
Syngo Osteo CT workstation in manually selected re-
gions of interest (ROIs). Hounsfield units (HU) were
used for bone density measurements. Siemens Somatom
Sensation Open (Siemens, Erlangen, Germany) was used
for all CT examinations. Measurements were carried out
at the appropriate site by a single physician. During the
observation period, because most participants received
anti-osteoresorptive treatment, changes in bone density
in unaffected lumbar (L1–3) vertebrae were also mea-
sured. In the case of lumbar osseous metastases (L1–3),
measurements were taken in other unaffected areas.
Pathologic fractures were diagnosed by experienced ra-
diologists by means of CT and/or MRI imaging and
comparing to baseline imaging tests. New fractures were,
by definition, not present on initial imaging, whereas
progressive fractures referred to visibly increasing size
and/or number of fracture gaps, dislocation of fracture
fragments, or increasing sintering of the VCF. A VCF
was defined as the reduction of the vertebral body height
by more than 20%. Each of these was grouped under the
term of “pathologic fractures”.
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Radiotherapy
CT simulation was carried out with custom immobilization
using Aquaplast® head masks, vacuum mattresses, and/or
Wingstep® arm abduction framework. OARs (including the
spinal cord) and the clinical target volume (CTV) were de-
lineated on the planning CT with MRI co-registration. The
planning target volume (PTV) was to be covered by the
80% isodose, and 24 Gy in a single fraction was prescribed
to this isodose line. OAR tolerance doses were per the
RTOG 0631 trial [13]. SBRT techniques included helical
Tomotherapy, step-and-shoot intensity-modulated radio-
therapy, or volumetric-modulated arc therapy. Treatment
was delivered by an Elekta Versa HD accelerator. Image
guidance was performed in all patients by means of mega-
voltage CT and/or TomoTherapy platforms.
For the 3DCRT arm, treatment was performed as ir-
radiation of the involved vertebral body as well those
immediately above and below to a total dose of 30 Gy in
10 fractions, most commonly delivered with 3/4 antero-
posterior/posteroanterior beams. Position verification was
carried out weekly before radiotherapy by kilovoltage
cone-beam CT (kV-CBCT) and before each fraction by
orthogonal portal images being compared with digitally
reconstructed radiographs (DRR) from the planning CT.
Statistical analysis
Complete details regarding statistical analysis are presented
elsewhere [16]. Owing to the exploratory nature of this
study, a complete power calculation was not possible; how-
ever, with 30 patients in each group, it was possible to de-
tect a standardized mean-value effect of 0.8 with 80%
power at a significance level of 0.05.
All variables were analyzed descriptively by tabulation
of the measures of the empirical distributions. According
Fig. 1 Trial profile
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to the scale level of the variables, means (Hodges-Leh-
mann estimates) and standard deviations or absolute
and relative frequencies, respectively, were reported.
Additionally, for variables with longitudinal measure-
ments, the time courses of individual patients and sum-
marized by treatment groups. Descriptive p-values of the
corresponding statistical tests comparing the treatment
groups were given. Analysis of covariance (ANOVA)
with repeated measurements, with treatment group as a
factor, and pain medication as covariates, were done.
The Wilcoxon rank-sum test was used to detect possible
differences between groups after 3 and 6 months. All
statistical analyses were done using SAS software Ver-
sion 9.4 or higher (SAS Institute, Cary, NC, USA).
Funding source
The sponsors of the study had no role in study design,
data analysis, data interpretation and wording of the re-
port. The corresponding author (HR) had full access to
the entire data of the study and had final responsibility
regarding the decision to submit for publication.
Results
Baseline characteristics were balanced between the two
treatment arms (Table 1, as previously published [17]).
Although all surviving patients completed all assess-
ments, not all patients survived at the three and 6
month time periods. Within the first 3 months, 4 pa-
tients (14.8%) in the SBRT group had died, along with 5
patients (17.9%) in the 3DCRT arm. Between 3 and
6 months, another 4 patients (14.8%) died due to tumor
progression in the SBRT cohort, along with a further 3
patients (10.7%) in the 3DCRT arm (Fig. 1). Mortality
did not differ between groups. One participant in the
intervention arm did not receive a CT examination at
6 months after RT. The mean follow-up was 8.1 months
(95% CI 6.87–8.97) for both groups.
As compared to baseline, bone density became signifi-
cantly higher at 3 and 6 months following SBRT by a me-
dian percentage of 33.8% (IQR 12.0–69.6) and 72.1% (IQR
15.2–95.7) (p < 0.01 for both), respectively (Table 2).
These figures in the 3DCRT cohort were 32.9% (IQR 5.3–
48.1) and 41.2% (18.9–55.0) (p < 0.01 for both), respect-
ively. There were no statistical differences in bone density
between SBRT and 3DCRT at 3 (p = 0.629) or 6 months
(p = 0.327).
Subgroup evaluation of solely osteolytic lesions in the
SBRT arm at 3 and 6 months confirmed a significant im-
provement in bone density as compared to baseline (p =
0.031 for both), corresponding to 53.9% (IQR 33.8–86.7)
and 85.8% (IQR 59.9–95.7), respectively. In contrast,
there were no differences between these values in the
3DCRT group (p = 0.125 and p = 0.250, respectively).
There were no differences between bone density changes
in the SBRT and 3DCRT groups at 3 (p = 0.594) or 6
(p = 0.519) months (Table 2).
Bone density in unaffected vertebrae did not show
substantial changes within groups at 3 and 6 months fol-
lowing RT (SBRT: p = 0.334 and p = 0.932, 3DCRT: p =
0.956 and p = 0.616). There were also no significant dif-
ferences between the SBRT and 3DCRT arms at 3 (p =
0.410) or 6 months (p = 0.661).
Preexisting pathological fractures existed in 40.7% pa-
tients in the SBRT arm vs. 17.9% in the 3DCRT group
(p = 0.062) (Table 3). By 3 and 6 months, these numbers
rose to 47.8% vs. 21.7% (p = 0.063) and 61.1% vs. 30.0%
(p = 0.054), respectively. The incidence of new patho-
logical fractures at 3 months was 8.7% (n = 2) in the
SBRT arm vs. 4.3% (n = 1) in the 3DCRT arm. In the
SBRT group, new pathological fractures at 6 months
after SBRT were detected in 5 patients, (27.8%), of which
2 (40%) fractures were de novo and 3 (60%) were a pro-
gression of preexisting VCFs. These new pathological
fractures initially occurred in osteolytic metastases and
only in mixed metastases after 6 months (Table 3). Only
1 (5%) new pathological fracture was identified at
6 months after 3DCRT. No pathological fractures in ei-
ther group required salvage surgical intervention.
Discussion
This prespecified secondary evaluation of a prospective
randomized trial is the first to investigate the impact of
high-dose single-fraction SBRT on bone density as com-
pared to 3DCRT. Despite the high ablative doses in the
SBRT arm, the significant increase in bone density after
3 and 6 months was similar to that of 3DCRT. There
was a trend towards higher baseline pathologic fractures
in the SBRT cohort. Additionally a moderate rate of new
fractures occurred in SBRT cohort. These findings sug-
gest the safety of spinal SBRT from a novel perspective
heretofore unaddressed in the literature.
In general, rim sclerosis, “filling in”, and an increase in
bone density is regarded as a radiological response for
osseous lesions [18, 19]. Particularly in the case of
stability-reducing osteolysis, recalcification and struc-
tural remodelling of the bone is essential.
The subgroup analysis of osteolytic lesions in our
study at 3 and 6 months after SBRT revealed a signifi-
cant improvement in bone density, but without a signifi-
cant difference in comparison to the 3DCRT group.
Wachenfeld et al. reported an increase in CT density in
osteolytic metastases to approximately 150% of the ini-
tial value at 3 months after multi-fraction irradiation
[18]. Koswig and Budach showed improvement of bone
density in osteolytic metastases by 173% at 6 months
after multi-fraction irradiation [19]. In this trial, similar
results regarding bone density were achieved. The bone
density of osteolytic spinal lesions at 3 months after
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SBRT and 3DCRT increased by 53.9% and 46.9%, re-
spectively. It is unclear why SBRT outperformed 3DCRT
within in osteolytic lesions, but could be related to
short-course dosing.
However, potential imbalances in anti-osteoresoptive
therapies are unlikely, as densities of unaffected vertebrae
yielded no differences between groups. Rief et al. investi-
gated the impact of resistance training concomitantly with
Table 1 Demograhics
SBRT group n = 27 3DCRT group n = 28 p-value
n % n %
Age (years)
Mean (SD) 61 (8,2) 63,9 (10,8) 0,225
Gender
Male 15 55,6 13 46,4 0,499
Female 12 44,4 15 53,6
Weight (kg, SD) 76 (19,2) 78,2 (16,4)
Height (cm, SD) 171,1 (8,5) 172,3 (8,7)
Body mass index (BMI)
Mean (SD) 25,8 (5,8) 26,5 (5,7) 0,899
Primary site
Lung cancer 9 33,3 10 35,7
Breast cancer 7 26,3 10 35,7
Renal cancer 2 7,4 2 7,1
Other 9 33,3 6 21,4
Localization metastases 0,317
Thoracic 14 51,9 19 67,9
Lumbar 13 48,1 8 28,6
Number metastases 0,301
1 metastasis 24 88,9 22 78,6
2 metastases 3 11,1 6 21,4
Distant metastases at baseline
Viszeral 12 44,4 14 51,9 0,586
Lung 11 40,7 4 14,8 0,033
Brain 7 25,9 3 11,1 0,161
Tissue 5 18,5 4 14,8 0,715
Hormontherapy 6 22,2 8 28,6 0,589
Immuntherapy 8 29,6 8 28,6 0,931
Chemotherapy 11 40,7 13 46,4 0,671
Surgery 8 29,6 10 35,7 0,631
Neurological deficit at baseline 0 0 1 3,6 0,322
Bisphosphonate at baseline 11 40,7 13 46,4 0,671
Orthopedic corset at baseline 3 11,1 6 21,4 0,301
Medication at baseline
Sleeping medication 1 3,7 1 3,6 0,979
Psychiatric medication 3 11,1 5 17,9 0,478
Opiate 11 40,7 10 35,7 0,701
NSAID 15 55,6 15 53,6 0,883
Baseline characteristics of randomly assigned participants. Explanation: Others: cholangiocarcinoma, carcinoma of unknown primary, colon cancer, hepatocellular
carcinoma, melanoma cancer, pancreatic cancer, neuroendocrine cancer, prostate cancer, urothelial cancer
Abbreviations: NSAID nonsteroidal inflammatory drug
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conventional multi-fraction 3DCRT on bone density in a
randomized controlled study and found no significant dif-
ferences in the uninvolved spine [20]. Therefore, it has
been suggested that bisphosphonates may not exert de-
cisive effects in this setting.
The preexisting pathological fracture rate in our study
was 29%. Similar rates of preexisting VCFs (24%) were
detected in a large retrospective study of 594 treated
spinal tumors by Jaward et al. [21]. VCF rates in relevant
studies varies between 7 and 39% [22–26]. The retro-
spective analysis by Virk and colleagues of 323 spinal le-
sions treated with single-fraction SBRT (24 Gy)
demonstrated a cumulative incidence of symptomatic
VCF in the irradiated level of 7.2% [22]. The cumulative
incidence of VCF at 3 and 6 months after SBRT was
0.3% and 1.9%, respectively. In our trial, the incidence of
new pathological fractures at 3 and 6 months following
SBRT was higher by 8.7% (n = 2) and 27.8% (n = 5) re-
spectively. All fractured vertebral bodies in the SBRT
group were initially classified as potentially at risk ac-
cording to the SINS score [27], which confirms that the
SINS score is a useful instrument in predicting SBRT in-
duced pathological fractures. Rose et al. reported sub-
stantially higher rates of fracture progression after
single-fraction SBRT (18–24 Gy) by 39% [23]. Another
study detected VCF in 20% of 123 treated spinal seg-
ments with a median of 3 months up to the occurrence
of VCF [24]. Cunha et al. documented only 11% (n = 19)
of VCFs after SBRT [25], whereas another publication
observed 18% (n = 34) of 187 osteolytic spinal metastasis
Table 2 Bone density in metastatic bone before RT, as well as 3 and 6 months after RT
SBRT
group
Within
group
3DCRT
group
Within
group
Differences
between groups
n Median IQR p-value n Median IQR HL 95% CI p-
value
All metastases
HU Baseline 27 219.0 141.0–
364.0
28 248.0 155.0–
307.0
−11 −66.0-55.0 0.762
HU T2 23 231.0 196.0–
420.0
23 310.0 234.0–
428.0
−29 −100.0-63.0 0.455
HU T3 18 336.5 215.0–481 20 363.5 218.5–
463.5
−2.5 − 117.0-
105.0
0.942
3 months
HU T0-T2 23 65.0 22.0–107.0 < 0.01 23 64.0 16.0–108.0 < 0.01 5.0 −40.0-52.0 0.860
HU T0-T2 (%) 23 33.8 12.0–69.6 < 0.01 23 32.9 5.3–48.1 < 0.01 5.4 −17.6-30.0 0.629
6 months
HU T0-T3 18 95.0 50.0–208.0 < 0.01 20 97.5 59.5–158.0 < 0.01 19.5 −50.0-106.0 0.714
HU T0-T3 (%) 18 72.1 15.2–95.7 < 0.01 20 41.2 18.9–55.0 < 0.01 29.2 −21.4-58.4 0.327
Subgroup analysis
Osteolyltic metastases
HU
Baseline
8 164.0 116.0–
240.0
4 149.0 127.0–
248.0
−0.5 − 147.0-
197.0
1.000
HU T2 6 234.0 156.0–480 4 219.0 181.0–
503.0
23.5 −334.0-616.0 0.749
HU T3 6 312.5 200.0–
481.0
3 222.0 204.0–794 14.5 − 351.0-
614.0
0.699
3 months
HU T0-T2 6 69.5 64.0–133.0 0.031 4 70.0 54.0–255.0 0.125 1.0 −213.0-370.0 1.000
HU T0-T2 (%) 6 53.9 33.8–86.7 0.031 4 46.9 42.2–88.3 0.125 8.6 −60.4-94.6 0.594
6 months
HU T0-T3 6 165.5 88.0–208.0 0.031 3 64.0 64.0–456.0 0.250 −24.0 − 156.0-
396.0
0.899
HU T0-T3 (%) 6 85.8 59.9–95.7 0.031 3 45.7 40.5–134.9 0.250 −29.0 − 146.2-92.1 0.519
This results demonstrated the bone density (HU = Hounsfield units) in metastatic bone before RT (baseline), 3 and 6 months after RT. The results were presented
by absolute and relative values (%) of HU within and between group as median (Hodges–Lehmann estimate) and IQR
Abbreviations: HU Hounsfield units, IQR interquartile range, T0 baseline, T2 3 months, T3 6 months, T0–T2 difference baseline minus 3 months, T0-T3 difference
baseline minus 6 months, HL Hodges-Lehmann estimator, 95% CI 95% Confidence Interval
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with median follow up of 8 months [26]. Notably the
highest VCF rate 43% (n = 10) occurred after SBRT
(24 Gy in 1 fraction).
Symptomatic painful VCF following RT often requires
spinal stabilizing intervention. Minimally invasive
methods such as kyphoplasty and vertebroplasty are very
effective for these purposes [28–31]. Boehling et al.
found that preexisting fractures led to earlier fracture
progression, with a median progression-free survival
time from initial fracture of 14 months, as compared
with 25 months without preexisting fractures [24]. In
contrast, Sahgal et al. reported the median time to VCF
of 2.5 months (range 0.03–43.01 months), with the ma-
jority (65%) occurring within the first 4 months follow-
ing SBRT [32]. Half of those patients underwent salvage
surgery [32]. These findings may similarly justify early
prophylactic augmentation after SBRT to avoid the se-
quelae mentioned above [24]. Gerszten et al. showed
that fixation procedure is safe and effective even before
single-fraction SBRT in patients with preexisting patho-
logical fractures [29]. Initial apparent improvement in
pain after kyphoplasty and prior SBRT was reported in
96%, and long-term improvement in spinal pain oc-
curred in 92%. Performing SBRT subsequently may thus
allow for immediate stabilization of the fracture and de-
livery of ablative doses for local tumor control [29].
Another approach involving simultaneous kyphoplasty
and intraoperative radiotherapy is safe as well; Bludau et al.
observed immediate and sustained pain relief with excellent
local control (reduction of ≥3 points on the first postopera-
tive day) [33].
However, although kyphoplasty may alleviate pain
from pathological fractures, it may still fail. This may es-
pecially be true for delayed kyphoplasty failure, from
which retropulsed cement and neural compression are
serious complications requiring more extensive opera-
tions. Rajah et al. observed delayed kyphoplasty failure
in 5%, of which 2 (50%) patients received radiotherapy
[34]. The mean time to kyphoplasty failure was 2.9 ±
1.2 months [34]. Rajah et al. also identified possible pre-
dictors such as wall integrity, competency of the poster-
ior tension band, and junctional spinal level [34].
However, the use of kyphoplasty is anatomically lim-
ited to vertebral bodies; SBRT continues to be a reliable
alternative for metastases in posterolateral structures.
Nevertheless, both kyphoplasty and SBRT are intended
to help relieve pain and thereby improve quality of life.
The optimal timing (pre−/intra−/post) of prophylactic
surgical intervention with SBRT for carefully selected
vulnerable patients remains difficult to ascertain.
Although strengths of our investigation include the
randomized design and standardized evaluation of bone
density and recording of all pathological structures, sev-
eral limitations must be acknowledged. In addition to a
lower sample size and shorter follow-up, robust conclu-
sions based on statistical comparisons cannot be made,
Table 3 Results of pathological fractures of both groups
SBRT group 3DCRT group p-value
N n/n (new) % 95% CI N n/n (new) % 95% CI
Pathological fracture
All metastases
Baseline (T0) 27 11 40.7 0.224–0.621 28 5 17.9 0.061–0.369 0.062
3 months (T2) 23 11/(2) 47.8 0.268–0.694 23 5/(1) 21.7 0.075–0.437 0.063
6 months (T3) 18 11/(5) 61.1 0.358–0.827 20 6/(1) 30.0 0.119–0.543 0.054
Subgroup analysis
Osteolytic metastases
Baseline (T0) 8 2 25.0 0.032–0.651 4 0 0 0 0.273
3 months (T2) 6 3/(2) 50.0 0.118–0.882 4 1/(1) 25.0 0.006–0.806 0.429
6 months (T3) 6 3 50.0 0.118–0.882 3 1 33.3 0.008–0.906 0.635
Osteoblastic metastases
Baseline (T0) 2 0 0 5 0 0
3 months (T2) 2 0 0 4 0 0
6 months (T3) 1 0 0 4 0 0
Mixed metastases
Baseline (T0) 17 9 52.9 0.278–0.770 18 4 22.2 0.064–0.476 0.060
3 months (T2) 15 8 53.33 0.266–0.787 14 3 21.4 0.047–0.508 0.077
6 months (T3) 11 8/(5) 72.7 0.390–0.940 12 4/(1) 33.3 0.099–0.651 0.059
Abbreviations: N alive patients in group, n (new) number of new pathological fractures in the total number of pathological fractures, CI confidence interval
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along with the concession that pathologic fractures can
indeed occur after 6 months. Additionally, few studies
can entirely account for other factors influencing bone
density such as diet, vitamin supplementation, or par-
ticular medications. There may also be heterogeneity in
these patients given the specific location of vertebral me-
tastases (e.g. laminar/pedicle lesions versus those in the
vertebral body) as well as degree of soft tissue extension.
Although these may limit applicability to other studies,
larger randomized data are recommended to corroborate
these results.
Conclusions
This prespecified secondary evaluation of a prospective
randomized trial is the first to investigate the impact of
high-dose single-fraction SBRT on bone density as com-
pared to 3DCRT. Despite the high ablative doses in the
SBRT arm, the significant increase in bone density after
3 and 6 months was similar to that of 3DCRT. There
was a trend towards higher baseline pathologic fractures
in the SBRT cohort. Additionally a moderate rate of new
fractures occurred in SBRT cohort. These findings sug-
gest the safety of spinal SBRT from a novel perspective
heretofore unaddressed in the literature. Future random-
ized investigations with larger sample sizes are
recommended.
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